Showing results for "Science Challenge" in Physical Illness & Disease

Gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) infection are significant gastrointestinal challenges that impact patient quality of life, requiring proper diagnosis and treatment. In this 60-minute, case-based educational activity, multidisciplinary faculty guide clinicians through contemporary diagnostic techniques and evidence-based treatment strategies for both nonerosive and erosive GERD, as well as H. pylori infection.

While everyone knows of the Ice Bucket Challenge, the viral craze that swept the nation in summer 2014, too few know the truly inspirational story behind it. Pete Frates was a man at war with his own body, a man whose love for others was unshakable. He was a man who refused to fight alone and, in so doing, mobilized a global army to combat one of the most devastating diseases on earth: ALS, or Lou Gehrig's disease.

The Rise to the challenge series powered by EIT Health InnoStars gives you first-hand advice if you want to succeed with your start-up. Together with our guests – VCs, start-uppers and global companies, we deliver to your doorstep a road map so you can plan your business journey in the healthcare industry. Our hosts are Ines Matias & Tamas Bekasi, Business Creation Managers at EIT Health InnoStars.

The Private Cancer Physician’s Association (PCPA) is an oncology specialist organisation that aims to make high impact policy change for private practice, education and in delivering to patients the latest treatments and world-class clinical trials. The Cancer Patient Management Podcast series shares the latest updates in innovation for oncology specialists and the ecosystem in which they work to deliver best practice care for their patients. The information in this podcast is current at the time of recording, however we can’t guarantee that it will always apply to you. Be aware that you ...

An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity management.